Red Blood Cell Patents (Class 436/520)
  • Patent number: 10539574
    Abstract: A method for the in vitro detection of cartilage tissue and/or for the in vitro determination of the purity of cartilage tissue includes: a) treating a tissue sample with a protease and b) testing the protease-treated tissue sample for the presence of protease-resistant fragments of type II collagen and/or type I collagen. Methods can be carried out for preparing a cartilage cell culture, and for preparing a cartilage cell-loaded implant. Protease-resistant fragments of type II collagen and/or type I collagen can be used for the in vitro detection of cartilage tissue and/or for the in vitro determination of the purity of cartilage tissue. A kit can be used for carrying out the methods.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 21, 2020
    Assignee: TETEC Tissue Engineening Technologies AG
    Inventors: Karin Benz, Christian Freudigmann, Christoph Gaissmaier, Jochen Hecky, Jürgen Mollenhauer
  • Patent number: 9387264
    Abstract: The invention provides a fusion ferritin protein wherein a ferritin heavy chain polypeptide is fused to a peptide, wherein the peptide is fused to the C-terminal end of the ferritin heavy chain; and the peptide includes at least a portion of a Mms6 protein sequence and at least one heterologous amino acid at its N-terminal end. The invention further provides methods of use of the ferritin fusion protein for Magnetic Resonance Imaging.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: July 12, 2016
    Assignees: YEDA RESEARCH AND DEVELOPMENT CO. LTD., THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV
    Inventors: Michal Neeman, Raz Zarivach, Marina Radoul, Batya Cohen, Moriel Vandsburger, Limor Lewin
  • Patent number: 9315551
    Abstract: The present invention is based on the ORF3 gene of Porcine Circovirus Type 2 (PCV2) and the identification of tis apoptotic role. This discovery has led to the development of an attenuated live vaccine against PCV2.
    Type: Grant
    Filed: June 6, 2006
    Date of Patent: April 19, 2016
    Assignee: Temasek Life Sciences Laboratory Ltd.
    Inventors: Hwei-Sing Kwang, Isabelle Gek Joo Chen, Hui Kheng Chua, Jue Liu
  • Patent number: 8945857
    Abstract: The invention provides methods for isolating cells, particularly antibody-secreting cells that have a high likelihood of secreting antibodies specific for a desired antigen for the purpose of making monoclonal antibodies.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: February 3, 2015
    Inventor: John Schrader
  • Patent number: 8828730
    Abstract: Disclosed is a method for measuring thrombin generation in a whole blood sample. The whole blood sample may be applied forthwith, without prior processing. The blood cells and blood plasma in the whole blood sample are separated by (lateral) flow migration. Also disclosed is an assembly of a sample support and a device dedicated to measure thrombin generation in a whole blood sample. Advantageously, the sample support comprises a separator medium allowing separation of whole blood into blood cells and blood plasma by means of (lateral) flow migration.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: September 9, 2014
    Assignee: Synapse B.V.
    Inventors: Hendrik Coenraad Hemker, Rafael Jesus Apitz-Castro, Sebastiaan Nijhuis
  • Patent number: 8673575
    Abstract: The invention relates to medicine, in particular to a method for carrying out a preliminary instant diagnosis of oncologic diseases. The method involves sampling a patient's blood, mixing the sample with a reagent and recording reaction results. A supernatant liquid, which is produced by cultivating the finite cell line of a porcine embryo kidney culture in anaerobic conditions, is used as a reagent. The presence of oncologic disease is determined according to a positive reaction of erythrocytes and a negative or positive reaction of a citrated blood with the reagent. The inventive method makes it possible to make a preliminary conclusion about the presence of oncologic disease within a short time.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: March 18, 2014
    Inventors: Vladislav Nikolaevich Laskavy, Sergei Ivanovich Ivanenko
  • Patent number: 8617805
    Abstract: The present invention relates to novel methods for detecting at least one member of a known binding pair in a sample, including a cell, where one member of the pair (termed the “receptor”) is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the “ligand” or “target”). Rather than detecting the binding of at least one phage using antibody-based technology, the present invention relates to detecting the nucleic acid associated with the phages. In one aspect, the invention relates to identifying at least one antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophages, using antiglobulin reagent-displaying bacteriophages and detecting at least one nucleic acid associated with the phage.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: December 31, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Donald L. Siegel
  • Patent number: 8586293
    Abstract: The present invention relates to novel methods for detecting a member of a known binding pair in a sample, including a cell, where one member of the pair (termed the “receptor”) is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the “ligand” or “target”). Rather than detecting the binding of the phage using antibody-based technology, the present invention relates to detecting the nucleic acid associated with the phage. In one aspect, the invention relates to identifying an antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophage, as well as detecting anti-red blood cell auto- or alloantibodies and/or complement in a sample, using antiglobulin reagent-displaying bacteriophage and detecting a nucleic acid associated with the phage.
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: November 19, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Donald L. Siegel
  • Patent number: 8580531
    Abstract: The invention relates to a method for detecting a plurality of antigenic molecules carried by erythrocytes and/or a plurality of anti-erythrocyte antibodies, said antigenic molecules carried by the erythrocytes consisting of antigenic molecules carried not only by the erythrocytes, but also by at least one other cell population, other than the blood group antigen molecules, said method comprising bringing a sample into contact with distinguishable beads, on which are attached a) antibodies specific for said antigens, or b) erythrocytes or erythrocyte membrane fragment.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: November 12, 2013
    Assignee: Bio-Rad Innovations
    Inventors: Frederic Buffiere, Yves Raisin, Eliane Rivalin, Amparo Sanjuan
  • Patent number: 8580530
    Abstract: The invention relates to a method for detecting a plurality of antigenic molecules carried by erythrocytes and/or a plurality of anti-erythrocyte antibodies of an individual, comprising bringing a sample into contact with distinguishable beads, on which are attached a) antibodies specific for said antigens, or b) erythrocytes, erythrocyte membrane fragments or blood group antigens.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: November 12, 2013
    Assignee: Bio-Rad Innovations
    Inventors: Frederic Buffiere, Yves Raisin, Eliane Rivalin, Amparo Sanjuan
  • Patent number: 8574913
    Abstract: Hemoglobin in a sample solution is quickly and reliably denatured; at the same time, quick and accurate measurement of hemoglobin and a hemoglobin derivative is realized. In a method for measuring hemoglobin and a hemoglobin derivative, and a reagent composition, a measurement kit, an analysis device, and an analysis system used in the method, a sample solution containing a blood component is treated with a nonionic surfactant, an oxidizing agent, and a metal salt to denature hemoglobin in the sample solution to measure the hemoglobin, and thereafter the amount of a hemoglobin derivative in the sample is measured by an immunological method using an antibody specifically binding to a denatured site of the denatured hemoglobin derivative.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: November 5, 2013
    Assignee: Panasonic Corporation
    Inventors: Hirotaka Tanaka, Masanori Tanaka
  • Patent number: 8465988
    Abstract: Methods are provided herein for determining antioxidant activity of a test sample in intact cells. The method includes determining the antioxidant capacity of a test sample in intact red blood cells, wherein the test sample is added to intact red blood cells and oxidative damage is measured by alteration of fluorescence intensity of an oxidation-sensitive fluorescent indicator dye.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: June 18, 2013
    Assignee: Natural Immune Systems, Inc.
    Inventor: Gitte S. Jensen
  • Patent number: 8383058
    Abstract: Disclosed is a method for testing a modified specimen such as a dried blood spot, plasma or serum specimen, for an analyte of interest, such as cholesterol. In accordance with the disclosed subject matter, the level of the analyte of interest in the medium from which the modified specimen was obtained (e.g., from a patient's blood) is determined based on the level of an analyte in a solution formed from the modified specimen and on the level of at least one normalizing analyte. The analyte and normalizing analyte each may be an ion, compound, biochemical entity, or property of the specimen. Also disclosed are a fluid collector and a fluid collection device.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: February 26, 2013
    Assignee: Home Access Health Corporation
    Inventors: Ilia Vinogradov, Michael Wandell, Barbara Godsey
  • Patent number: 8383410
    Abstract: The invention concerns an internal standard used to quantitative analysis of the risk of humoral (i.e. vascular) transplant rejection. The internal standard consists of a stable composition of the C4d complement bound to a carrier consisting of erythrocytes or microparticles. The invention also concerns a method for analyzing in vitro the risk of humoral organ transplant rejection, which consists in determining the amount of component of C4d component fixed on the erythrocytes contained in a blood sample from a patient.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: February 26, 2013
    Assignee: Universite de Reims Champagne-Ardenne
    Inventors: Jacques Henri Max Cohen, Brigitte Reveil, Aymric Kisserli, Fadi Haidar, Béatrice Donvito
  • Patent number: 8084223
    Abstract: Methods and reagents are disclosed for detecting a false result in an assay for determining a concentration of an analyte in a whole blood sample suspected of containing the analyte. The method comprises determining by means of the assay a concentration of the analyte utilizing a hemolyzed portion of the blood sample to obtain concentration value 1 and determining by means of the assay a concentration of the analyte utilizing a non-hemolyzed portion of the blood sample and multiplying the concentration times a hematocrit factor to obtain concentration value 2. A ratio of concentration value 1 divided by concentration value 2 is determined and is compared to a predetermined ratio of known reliability. If the ratio is less than the predetermined ratio, a false result is indicated.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: December 27, 2011
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventor: Tie Quan Wei
  • Patent number: 8053201
    Abstract: Provided is a microfluidic control chip, which includes a filter section having a filter to which anti-immunoglobulin antibodies, which are bound to endogenous antibodies in blood to thereby remove the endogenous antibodies, are immobilized, a first reaction section to which detection antibodies immobilized to fluorescent nano-particles are adsorbed, the detection antibodies being bound to proteins to be detected in blood which is introduced from the filter section with the endogenous antibodies removed therefrom, and a second reaction and detection section including capture antibodies immobilized thereto, binding the capture antibodies to the proteins, which are bound to the detection antibodies introduced from the first reaction section, and detecting a concentration of the proteins based on an intensity of fluorescent light. Thus, the microfluidic control chip can minimize interference of an immune response to maximize the immune response.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: November 8, 2011
    Assignee: Electronics and Telecommunications Research Institute
    Inventor: Min Suk Jeong
  • Patent number: 7943368
    Abstract: Methods for reducing time to result in blood bank diagnostic testing with an agitation device and a low ionic strength solution are disclosed. Specifically provided are methods for reducing incubation time for antigen-antibody reactions in an immunohematologic assay by subjecting the assay reactants to incubation with agitation and optionally additionally a low ionic strength diluent.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: May 17, 2011
    Assignee: Micro Typing Systems, Inc.
    Inventors: Harry Malyska, Paula Howard
  • Patent number: 7919266
    Abstract: A process for the detection of antibodies in a test sample by preparing a suspension of erythrocytes with a test serum or plasma by mixing a test serum or plasma with erythrocytes; incubating the suspension of erythrocytes at a temperature of from 37° C. to 45° C. to bind any antibodies in the test serum or plasma to the surface of said erythrocytes; combining the suspension of erythrocytes with an amount of a solution of a macromolecule which is effective to agglutinate the erythrocytes; packing the resultant red cell agglutinates by centrifuging the suspension of erythrocytes; and, determining the presence of anti-erythrocyte antibodies by observing if antibody-dependent erythrocyte agglutination has occurred.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: April 5, 2011
    Assignee: Clavina Diagnostics, Inc.
    Inventor: Parviz Lalezari
  • Patent number: 7888053
    Abstract: Disclosed are methods for detecting antibody in a sample, where the antibody targets an antigen expressed by red blood cells or red blood cell ghosts. Rather than detecting the binding events between a particular antigen antibody pair (as in traditional agglutination based assays) the methods herein allow for multiplexed detection of clinically important allo-immune antibodies to blood group antigens. Specifically the method involves generating fluorescently encoded red blood cells or red blood cell ghosts with known antigen presentation and using them to detect the presence of antibody in serum/plasma with a fluorescent sandwich type immunoassay. The assay results can be read using flow cytometric or fluorescent microscope based imaging techniques.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: February 15, 2011
    Assignee: BioArray Solutions, LLC
    Inventor: Sukanta Banerjee
  • Patent number: 7824873
    Abstract: A blood crossmatching apparatus, kit and methods for testing the compatibility of mammals for blood transfusion. Particulate layers in the apparatus allow nonagglutinated red blood cells to permeate through, while agglutinated red blood cells cannot. The apparatus also has a density solution. The density solution separates white blood cells from red blood cells in the whole blood when centrifuged, without lysing the red blood cells. Thus, the apparatus can be used to test whole blood.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: November 2, 2010
    Inventor: Anne S. Hale
  • Patent number: 7803637
    Abstract: The present invention comprises the use of sickle cells or sickle cell precursors loaded with a therapeutic agent that localizes in tumors and induces a tumoricidal response.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: September 28, 2010
    Assignee: Jenomic
    Inventor: David S Terman
  • Patent number: 7794720
    Abstract: The present invention relates to isolated canine animal plasma, a method for isolating canine animal plasma, plasma obtained form an immunised or hyperimmunised canine animal and treating a canine animal with the isolated canine animal plasma. The method includes the step of selecting a canine animal having a blood group compatible with a recipient canine animal having an unmatched blood group, namely, selecting a canine animal for a blood group that does not cause plasma transfusion reaction and/or haemolysis. In one form, the method includes the step of immunising or hyperimmunising a canine animal plasma donor with one or more antigens of a canine animal pathogen. The pathogen is preferably a bacteria or virus.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: September 14, 2010
    Assignee: Plasma Ventures Pty Ltd
    Inventor: Ross Phillip Wilson
  • Patent number: 7767436
    Abstract: Methods for reducing time to result in blood bank diagnostic testing with an agitation device and a low ionic strength solution are disclosed. Specifically provided are methods for reducing incubation time for antigen-antibody reactions in an immunohematologic assay by subjecting the assay reactants to incubation with agitation and optionally additionally a low ionic strength diluent.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: August 3, 2010
    Assignee: Micro Typing Systems, Inc.
    Inventors: Harry Malyska, Paula Howard
  • Patent number: 7709219
    Abstract: The invention includes Rh(D) binding proteins, including antibodies, and DNA encoding such proteins. Methods of generating such proteins and DNAs are also included.
    Type: Grant
    Filed: January 9, 2006
    Date of Patent: May 4, 2010
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Donald L. Siegel
  • Patent number: 7709273
    Abstract: Methods, compositions and kits are disclosed. The compositions are light emitting and comprise a polymeric matrix having dissolved therein a photoactive compound. The composition has the characteristic that, after activation of the photoactive compound, the rate of decrease in the intensity of light emission at any time during a 20-fold decrease in the intensity is proportional to the intensity of the light emission. In one embodiment the polymeric matrix is comprised of particles of about 20 nm to about 100 ?m in diameter to which is bound a specific binding pair member. The particles generally comprise a polymeric matrix having dissolved therein about 1 to about 20% by weight of a dopant. The compositions may be used in methods for determining an analyte. A combination is provided comprising (1) a medium suspected of containing the analyte, (2) and the aforementioned composition. The photoactive substance is activated and the effect of the activating on the optical properties of the combination is detected.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: May 4, 2010
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Sharat Singh, John S. Pease, Jacqueline Sadakian, Daniel B. Wagner, Edwin F. Ullman
  • Patent number: 7678574
    Abstract: The invention provides for a process for preparing a sensitivity control for blood group determination including dissolving an amount of an antigen in water to give an antigen solution of known concentration, contacting the antigen solution with cells to allow insertion of antigen molecules into the cell membranes of the cells to give transformed cells or contacting the antigen solution with cells that have been modified by the insertion of a linker molecule into the membranes of the cells to allow attachment of antigen molecules to the linker molecules to give transformed cells, washing the transformed cells to give a transformed cell solution, and determining the concentration of the transformed cell solution to enable the solution to be used as a sensitivity control for blood group determination.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: March 16, 2010
    Assignee: KIWI Ingenuity Limited
    Inventors: Deborah Adella Blake, Lissa Gwyneth Gilliver, Stephen Michael Henry, Ji Chen
  • Patent number: 7670798
    Abstract: The present invention describes semi- and fully-automated methods and reagents therefor for the assay and analysis of body fluid samples, particularly non-blood samples. The methods and reagents are especially useful for the assay and analysis of cerebrospinal fluid (CSF) samples. The reagent compositions sphere and fix all cells in the sample in suspension. Reported results can include red blood cell (RBC) and white blood cell (WBC) counts, WBC differential values, cell-by-cell volumes and dry-mass concentrations.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: March 2, 2010
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Leonard Ornstein, Gena Fischer, David Zelmanovic, Pamela Elsins, Jolanta Kunicka, Michael J. Malin
  • Patent number: 7664289
    Abstract: Methods and apparatus for analyzing nonoperational data acquired from optical discs, and in particular, trackable optical discs having concurrently readable nonoperational structures are provided. Analysis can involve identifying patterns in the data that reproducibly distinguish underlying structures, or identifying patterns in the data that report physical properties of the nonoperational structures. When an optical disc has a plurality of physically nonidentical concurrently readable nonoperational structures, analysis can involve identifying patterns in the data that distinguish among the physically nonidentical nonoperational structures. Also, relative physical locations of nonoperational structures on the disc can be calculated. A system for remotely analyzing data in order to expedite complex data analysis and reporting the results thereof is also provided.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: February 16, 2010
    Assignee: Vindur Technologies, Inc.
    Inventors: Mark O. Worthington, Gregory R. Basile
  • Patent number: 7618792
    Abstract: Disclosed are methods for detecting antibody in a sample, where the antibody targets an antigen expressed by red blood cells or red blood cell ghosts. Rather than detecting the binding events between a particular antigen antibody pair (as in traditional agglutination based assays) the methods herein allow for multiplexed detection of clinically important allo-immune antibodies to blood group antigens. Specifically the method involves generating fluorescently encoded red blood cells or red blood cell ghosts with known antigen presentation and using them to detect the presence of antibody in serum/plasma with a fluorescent sandwich type immunoassay. The assay results can be read using flow cytometric or fluorescent microscope based imaging techniques.
    Type: Grant
    Filed: January 6, 2006
    Date of Patent: November 17, 2009
    Assignee: BioArray Solutions Ltd.
    Inventor: Sukanta Banerjee
  • Patent number: 7611849
    Abstract: This invention relates to the field of biological assays where cells can be classified and enumerated using flow cytometry optical instrumentation. The invention combines information from multi-angle, light scatter from the cell itself and multi-angle light scatter from small, optically resonant particles that are selectively bound to surface molecules on the cell to carry out classification and enumeration. This light scatter method enables an instrumentation system that is simple to use, inexpensive to build, and mechanically robust; making it suitable for use in remote clinical environments.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: November 3, 2009
    Assignee: Point Care Technologies
    Inventors: W. P. Hansen, Petra B. Krauledat
  • Patent number: 7588905
    Abstract: A method for identifying or monitoring SLE in an individual is provided. The method includes quantitating complement component C4d on the surfaces of platelets and comparing the amounts of C4d to reference levels of C4d on platelets of individuals without SLE and/or on platelets of the individual obtained at a different time. Kits for use in the above-described methods are provided along with computer readable media tangibly embodying executable instructions to perform the methods.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: September 15, 2009
    Assignee: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Joseph M. Ahearn, Susan M. Manzi, Jeannine Navratil
  • Patent number: 7585640
    Abstract: The invention is related to methods of diagnosing inflammatory diseases or conditions by determining levels of components of the complement pathway on the surface of white blood cells.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: September 8, 2009
    Assignee: University of Pittsburgh
    Inventors: Joseph M. Ahearn, Susan M. Manzi, Chau-Ching Liu
  • Patent number: 7584019
    Abstract: Systems and methods allowing for the automatic control and scheduling of a staining apparatus for biological samples on slides present within the apparatus. In some embodiments, the actions of a robot coupled to the staining apparatus, which performs some of the staining tasks on the individual slides in accordance with their respective protocols, may be prioritized and scheduled. In some embodiments, the scheduling may result in increasing or maximizing the throughput of slides. In some embodiments, robot scheduling ensures that the individual slides are processed substantially within the tolerances specified by their respective protocols. In some embodiments, the robot scheduler may respond to spontaneous user actions and adaptively schedule or re-schedule robot actions.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: September 1, 2009
    Assignee: Dako Denmark A/S
    Inventors: Gordon Alan Feingold, James B. Gilmartin, Mark Richard Holbrook, John A. Favuzzi, Marc E. Key
  • Patent number: 7553629
    Abstract: The present invention relates to novel nucleic acid molecules encoding a Rhesus D antigen contributing to the weak D phenotype which are characterized by one or a combination of missense mutations or by a gene conversion involving exons 6 to 9 of the RHD and RHCE genes. The present invention further relates to vectors comprising the nucleic acid molecules of the invention, to hosts transformed with said vectors, to proteins encoded by said nucleic acid molecules and to methods of producing such polypeptides. The fact that missense mutations and the conversion referred to above can be directly correlated to the weak D phenotype has a significant impact on the routine testing of blood samples. For example, oligonucleotides and antibodies can now be designed that generally allow the detection of weak D phenotypes in a sample. Such oligonucleotides, antibodies as well as a variety of diagnostic methods all fall within the scope of the present invention.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: June 30, 2009
    Inventors: Willy A. Flegel, Franz F. Wagner
  • Patent number: 7547557
    Abstract: A diagnostic assay device that directs an applied sample to the analytical membrane of a directed flow device. The device has a sample receiving port defined by layers of built-up material on one end of the test strip. The port contains the sample and specifically directs it to the membrane in a controlled fashion. Additional features include configuration of the housing in a general C-shape with the test strip spanning the opening of the C-shape to allow access by a reader device. A preferred method employs superparamagnetic particles to label the target analytes for detection and measurement by means of an electromagnetic reader device.
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: June 16, 2009
    Assignee: Quantum Design, Inc.
    Inventors: Ronald T. LaBorde, Herbert S. Chow
  • Publication number: 20090053694
    Abstract: In the present invention, a reagent capable of immunospecific reaction with the analyte of interest is conjugated to a photocatalytic microparticle. After the immunospecific binding has occurred, the assay amplification is performed by exposing photocatalytic particles to actinic UV light in presence of an oxidizable compound. Photocatalytic particles are catalyzing multiple occurrences of oxidation of oxidizable compound under UV light irradiation resulting in detectable changes such as color change. This provides for amplification of each single act of immunospecific binding and is followed by colormetric detection. Thus a high sensitivity quantitative or qualitative immunoassay can be realized.
    Type: Application
    Filed: December 26, 2005
    Publication date: February 26, 2009
    Inventor: Leo B. Kriksunov
  • Patent number: 7449329
    Abstract: A blood crossmatching apparatus, kit and methods for testing the compatibility of mammals for blood transfusion. Particulate layers in the apparatus allow nonagglutinated red blood cells to permeate through, while agglutinated red blood cells cannot. The apparatus also has a density solution layered above particulate layers. The density solution separates white blood cells from red blood cells in the whole blood when centrifuged, without lysing the red blood cells. Thus, the apparatus can be used to test whole blood.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: November 11, 2008
    Inventor: Anne S. Hale
  • Patent number: 7390631
    Abstract: Methods for diagnosing and monitoring systemic lupus erythematosus (SLE) or scleroderma by determining, in a blood sample from the individual being diagnosed or monitored, complement component C4d deposited on surfaces of red blood cells in the sample, and optionally also determining complement receptor CR1 deposited on the red blood cell surfaces. For diagnosis this is compared with the quantity of C4d (and optionally CR1) present on red blood cells of normal individuals. For monitoring it is compared with a value in a sample or samples previously obtained from the individual patient. The comparison may be made with individual values for C4d and CR1 and/or with a ratio of the two found in normal individuals.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: June 24, 2008
    Assignee: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Joseph M. Ahearn, Susan M. Manzi
  • Patent number: 7300804
    Abstract: A method and apparatus for controlling the processing of a liquid sample, e.g., a blood sample, based on a measurement related to the sample's ability to coat a surface against which the sample is brought into contact while being routinely transported. Preferably, the sample is advanced through a tube, and the amount of sample residue remaining within the tube is measured and correlated to coating process subsequently carried out on the sample, e.g., a process for producing blood-smears on a microscope slide. In a preferred embodiment, the amount of sample residue in a blood-transport tube is used to control the motion profile (i.e., acceleration and velocity) of a drop-spreading member used to spread a blood drop on a microscope slide in an automated slide-making instrument.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: November 27, 2007
    Assignee: Beckman Coulter, Inc.
    Inventor: Jose Sellek-Prince
  • Patent number: 7247501
    Abstract: According to the present invention, there is provided a delivery vehicle including sickle red blood cells carrying a moiety. The moiety can be any type of diagnostic or therapeutic agent. The present invention further provides for a method of diagnosing systemic hypoxia, acidosis, or hypertonicity by administering sickle red blood cells to a patient and detecting the location of the sickle red blood cells. Additionally, the present invention provides for a method of therapeutic treatment of systemic hypoxia, acidosis, or hypertonicity by administering sickle red blood cells to a patient. Further, the present invention provides for a delivery vehicle that specifically localizes or concentrates at systemic hypoxia, acidosis, or hypertonicity areas. The delivery vehicle is used in diagnosing and therapeutically treating these areas of hypoxia, acidosis, or hypertonicity also. The present invention further provides for a method of making the delivery vehicle described herein.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: July 24, 2007
    Assignees: Henry Ford Health System, Wayne State University
    Inventors: Jae Ho Kim, Stephen Lawrence Brown, Paul S. Swerdlow
  • Patent number: 7160686
    Abstract: The present invention pertains to the field of medicine and may be used for producing a specific antiserum as well as for carrying out immunological diagnoses of malignant tumours. This method for producing an antiserum involves sampling an embryo at the foetal stage from animals of a same genetic type so as to obtain a cell suspension. After immunization, this method involves sampling spleen cells from the animal, separating lymphocytes and immunizing the animal of the same genetic line using the lymphocyte suspension. An antiserum is then obtained and cells originating from healthy organs of the same animals are added to the antiserum. The mixture is finally decanted and the liquid located above the sediments is filtered. In order to carry out a diagnosis, the filtrate is added to the subject's blood and the results are obtained by immuno-fluorescence, by blood tests or using other methods of immunological diagnosis.
    Type: Grant
    Filed: May 18, 1998
    Date of Patent: January 9, 2007
    Assignee: Widnes Company Inc.
    Inventors: Galina Mikhailivna Erkhova, legal representative, Valentin Sergeevich Erkhov, deceased
  • Patent number: 7060453
    Abstract: A method is provided for determining the level of an analyte in the blood of an individual based on determination of the level of the same analyte in non-blood sample (e.g. urine, saliva and hair) obtained from the individual. The non-blood sample contains red blood cells and the volume of the blood in the sample together with the amount of the analyte in the sample are the basis for calculating the level of the analyte in the individual's blood. Kits for carrying out the above method are also provided.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: June 13, 2006
    Inventor: Falk Fish
  • Patent number: 7022529
    Abstract: Methods, compositions and kits are disclosed. The compositions are light emitting and comprise a polymeric matrix having dissolved therein a photoactive compound. The composition has the characteristic that, after activation of the photoactive compound, the rate of decrease in the intensity of light emission at any time during a 20-fold decrease in the intensity is proportional to the intensity of the light emission. In one embodiment the polymeric matrix is comprised of particles of about 20 nm to about 100 ?m in diameter to which is bound a specific binding pair member. The particles generally comprise a polymeric matrix having dissolved therein about 1 to about 20% by weight of a dopant. The compositions may be used in methods for determining an analyte. A combination is provided comprising (1) a medium suspected of containing the analyte, (2) and the aforementioned composition. The photoactive substance is activated and the effect of the activating on the optical properties of the combination is detected.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: April 4, 2006
    Assignee: Dade Behring Marburg GmbH
    Inventors: Sharat Singh, John S. Pease, Jacqueline Sadakian, Daniel B. Wagner, Edwin F. Ullman
  • Patent number: 6955889
    Abstract: Simultaneous forward and reverse blood group testing is described using both a visual detection system and a fluorescent based labeling and detection system. Forward and reverse tests could be performed separately, but A and B agglutinates can be detected and discriminated simultaneously.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: October 18, 2005
    Assignee: Ortho-Clinical Diagnostics, Inc.
    Inventors: Thomas J. Mercolino, Kathleen J. Reis
  • Patent number: 6911178
    Abstract: Disclosed are novel protein and peptide compositions comprising soluble and bound forms of immunologically-active blood group antigens including mammalian Rh antigens. In preferred embodiments methods for the isolation and purification of serologically-active human Rh antigens such as D, c, C, E, and e are disclosed. Also disclosed are methods for the adsorption of immunologically-active Rh antigens to solid supports. Diagnostic kits, methods, and devices for the detection of Rh antibodies in clinical and non-clinical samples are also disclosed. Devices, compositions and methods for the isolation, purification and quantitation of anti-Rh antibodies from solution are also provided.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: June 28, 2005
    Assignees: Board of Regents, The University of Texas System, Baylor College of Medicine
    Inventors: L. Scott Rodkey, Marwan A. Yared, Kenneth J. Moise, Jr.
  • Patent number: 6878811
    Abstract: A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of bottrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.
    Type: Grant
    Filed: January 13, 1999
    Date of Patent: April 12, 2005
    Assignee: Ajinomoto Co., Inc.
    Inventors: Naoyuki Fukuchi, Fumie Futaki, Morikazu Kito, Koichi Ishii, Akiko Tanaka
  • Patent number: 6858439
    Abstract: The present invention recognizes that separation of components of a sample facilitate, and are often necessary for, sample analysis. Dielectrophoretic separation provides an efficient, reliable, nondisruptive, and automatable method for the separation of moieties in a sample based on their dielectric properties. The present invention provides compositions and methods for enhancing the dielectrophoretic separation of one or more moieties in a sample. A first aspect of the present invention is a solution that when mixed with a sample, modifies at least one dielectric property of one or more components of the sample and has a conductivity such that one or more moieties of the sample can be separated using dielectrophoresis. Such solutions can be used in the analysis of samples on chips, and can be used in methods that use binding partners, including microparticles that can be translocated by dielectrophoretic forces, traveling-wave dielectrophoretic forces or magnetic forces.
    Type: Grant
    Filed: October 10, 2000
    Date of Patent: February 22, 2005
    Assignee: Aviva Biosciences
    Inventors: Junquan Xu, Xiaobo Wang, Jing Cheng, Weiping Yang, Lei Wu
  • Patent number: 6830895
    Abstract: The present invention relates to a kit for determining feline blood type, wherein the kit includes a mixture comprised of a first monoclonal antibody and a second monoclonal antibody, wherein both antibodies recognize feline blood group specific A antigens. The present invention also relates to a method for determining feline blood type, wherein the method utilizes two distinct monoclonal antibodies, which recognize feline blood group specific A antigens.
    Type: Grant
    Filed: July 26, 2001
    Date of Patent: December 14, 2004
    Assignee: Kansas State University Research Foundation
    Inventors: Gordon A. Andrews, Joseph E. Smith
  • Patent number: 6825000
    Abstract: An immunoassay reagent is obtained whereby a microscale substance such as an antigen or antibody can be assayed at a high sensitivity, and whereby a need to separate a reacted substance, e.g., an immunoreacted substance, from an unreacted substance can be eliminated or such a separation can be simplified. An immunoassay reagent, for use in the quantitative determination of a target antigen or antibody present in a sample, containing an insoluble carrier which carries an enzyme and an antibody or antigen corresponding to the antigen or antibody, an enzyme inhibitor for inhibiting the activity of the enzyme and a substrate with which the enzyme reacts.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: November 30, 2004
    Assignee: Sekisui Chemical Co., Ltd.
    Inventors: Masayuki Yokoi, Takayuki Akamine, Katsumi Yoshikawa
  • Patent number: 6821790
    Abstract: A method of separating a cell-containing sample into a substantially cell-depleted portion, and a cell-containing portion comprising at least one of a stem cell, a lymphocyte, and a leukocyte comprises a step in which the sample is received in a vessel with at least one flexible wall. In another step, an additive and particles are added to the sample, wherein the additive substantially binds to the at least one of the stem cell, lymphocyte, and leukocyte, and the particles and wherein the particles substantially bind to the at least one of the stem cell, lymphocyte, and leukocyte, and the additive, thereby producing a cell-containing network. In a further step, the network is separated from the substantially cell-depleted portion by applying a magnetic force.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: November 23, 2004
    Inventors: Vijay Mahant, Byron Doneen